Home > Insider Trading > Filing (0001209191-21-008587)

Filing Details

Accession Number:: 0001209191-21-008587
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-08 18:08:01
Reporting Period:: 2021-02-08

Accepted Time:: 2021-02-08 18:08:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785345	Landos Biopharma Inc.	LABP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1678736	Konstantin Poukalov	C/O Landos Biopharma, Inc. 1800 Kraft Drive, Suite 216 Blacksburg VA 24060		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-08	13,369,728	$0.00	13,369,728	No	4	C	Indirect	By funds
Common Stock	Acquisiton	2021-02-08	1,250,000	$16.00	14,619,728	No	4	P	Indirect	By funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By funds
No	4	P	Indirect	By funds

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-02-08	5,883,538	$0.00	5,883,538	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-02-08	7,486,190	$0.00	7,486,190	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.
Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.
Consists of 5,799,564 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), 5,799,564 shares of common stock held by Perceptive Xontogeny Venture Fund, LP ("PXVF"), and 1,770,600 shares of common stock held by PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
Consists of 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PLSMF and 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Consists of 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PLSMF, 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PXVF and 1,770,600 shares of common stock issuable upon conversion of Series B preferred stock held by PXV. Perceptive Advisors serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.